Back to top
more

CymaBay Therapeutics Inc. (CBAY)

(Delayed Data from NSDQ)

$13.12 USD

13.12
454,386

+0.67 (5.38%)

Updated May 3, 2019 04:00 PM ET

After-Market: $13.12 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

CymaBay Therapeutics Inc. (CBAY) Reports Q4 Loss, Misses Revenue Estimates

CymaBay Therapeutics Inc. (CBAY) delivered earnings and revenue surprises of -9.38% and 85.75%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates

Earnings from Biogen (BIIB) and CymaBay (CBAY) are in focus in the biotech sector.

Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline

Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.

Company News for Feb 13, 2024

Companies In The Article Are: FANG, JOBY,C, CBAY and GILD

Does CymaBay Therapeutics Inc. (CBAY) Have the Potential to Rally 45.99% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 46% in CymaBay Therapeutics Inc. (CBAY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Are Medical Stocks Lagging Apyx Medical (APYX) This Year?

Here is how Apyx Medical (APYX) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.

CymaBay Therapeutics Inc. (CBAY) is on the Move, Here's Why the Trend Could be Sustainable

CymaBay Therapeutics Inc. (CBAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

CymaBay (CBAY) Stock Up on Positive Results From PBC Study

CymaBay (CBAY) reports encouraging data from the phase III study of seladelpar in PBC patients. Stock up.

Recent Price Trend in CymaBay Therapeutics Inc. (CBAY) is Your Friend, Here's Why

CymaBay Therapeutics Inc. (CBAY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

CymaBay Therapeutics Inc. (CBAY) Is a Great Choice for 'Trend' Investors, Here's Why

CymaBay Therapeutics Inc. (CBAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Here's Why Momentum in CymaBay Therapeutics Inc. (CBAY) Should Keep going

CymaBay Therapeutics Inc. (CBAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Tirthankar Chakraborty headshot

4 Best Breakout Stocks to Buy Now for Superlative Returns

CymaBay Therapeutics (CBAY), RxSight (RXST), UWM (UWMC) & Remitly Global (RELY) have been selected as the breakout stocks for today.

Wall Street Analysts Predict a 40.32% Upside in CymaBay Therapeutics Inc. (CBAY): Here's What You Should Know

The consensus price target hints at a 40.3% upside potential for CymaBay Therapeutics Inc. (CBAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Here's What Could Help CymaBay Therapeutics Inc. (CBAY) Maintain Its Recent Price Strength

If you are looking for stocks that are well positioned to maintain their recent uptrend, CymaBay Therapeutics Inc. (CBAY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?

Here is how Gilead Sciences (GILD) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.

Is Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year?

Here is how Akero Therapeutics, Inc. (AKRO) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.

CymaBay Therapeutics Inc. (CBAY) Upgraded to Buy: What Does It Mean for the Stock?

CymaBay Therapeutics Inc. (CBAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Is Swedish Orphan Biovitrum (BIOVF) Stock Outpacing Its Medical Peers This Year?

Here is how Swedish Orphan Biovitrum (BIOVF) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.

CymaBay Therapeutics Inc. (CBAY) Moves to Buy: Rationale Behind the Upgrade

CymaBay Therapeutics Inc. (CBAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

CymaBay Therapeutics Inc. (CBAY) Reports Q3 Loss, Misses Revenue Estimates

CymaBay Therapeutics Inc. (CBAY) delivered earnings and revenue surprises of -13.79% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for July 20th

AEVA, BIDU, CBAY, DRNA and RACE have been added to the Zacks Rank #5 (Strong Sell) List on July 20, 2021.

Kinjel Shah headshot

5 Disruptive Biotech Stocks With Solid Long-Term Potential

Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.

Implied Volatility Surging for CymaBay Therapeutics (CBAY) Stock Options

Investors need to pay close attention to CymaBay Therapeutics (CBAY) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in CymaBay (CBAY) Stock?

Investors need to pay close attention to CymaBay (CBAY) stock based on the movements in the options market lately.